COSOPT PF (dorzolamide HCl, timolol maleate) 2%, 0.5% ophthalmic solution by Merck Cosopt PF (dorzolamide HCl 2%, timolol maleate 0.5% ophthalmic solution), the preservative-free formulation of Cosopt ...
Dorzolamide HCl 2%, timolol maleate 0.5%; oph soln; preservative-free. Mild-to-moderate COPD or bronchospastic disease, or severe renal impairment: not recommended. Hepatic impairment. Surgery. May ...
LAKE FOREST, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX), a niche generic pharmaceutical company, today announced that it has acquired from Merck (NYSE: MRK), the U.S. rights to three branded ...
The company will pay nearly $53 million in the deal. All three products are eye drop solutions. AzaSite treats bacterial conjunctivitis, a type of infection, while COSOPT and COSOPT PF help lower ...
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it signed an agreement for Santen Pharmaceutical Co., Ltd. (Santen) ...
Akorn, a leading specialty pharmaceutical company, has completed its previously announced sale of seven branded ophthalmic products to Théa Pharma. Under the deal, Théa Pharma acquired seven products, ...
Please provide your email address to receive an email when new articles are posted on . Santen Pharmaceutical and Merck have entered into an agreement by which Santen will purchase Merck’s ...
Generic drug purveyor Akorn has expanded its portfolio of ophthalmic products thanks to a deal with Merck. The company announced it has acquired the U.S. rights to a trio of such treatments -- AzaSite ...
Merck Signs Sale Agreement with Santen for Merck's Ophthalmology Products in Japan and Key Markets in Europe and Asia Pacific WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results